Perilipin 2 (PLIN2) is a lipid droplet-associated protein which regulates cellular lipid 25 storage and is highly expressed in the liver. Previous studies of a missense single 26 nucleotide polymorphism (SNP) in PLIN2, Ser251Pro, (i.e. rs3556875) have shown this 27 SNP to cause decreased lipolysis and increased intracellular lipid accumulation. To 28 explore if this SNP is associated with nonalcoholic steatohepatitis (NASH), we 29 genotyped 116 adults with NASH and 67 age-and gender-matched controls. 30 rs3556875 was significantly associated with NASH with an allelic odds ratio of 2.98 (95% 31 confidence interval 1.12 -7.31, p=0.02) and in a dominant inheritance model. In an in vitro 32 model of hepatic steatosis, expression of the Pro251 variant protein led to phenotypic 33 changes in intracellular lipid droplets, yielding smaller diameter and up to 7 fold more lipid 34 droplets per cell when compared to wild type PLIN2. In conclusion, the Ser251Pro SNP of PLIN2 35 may convey risk for NASH and causes phenotypic changes in hepatocyte lipid droplets. 36 37 KEYWORDS 38 Non-alcoholic steatohepatitis, perilipin 2, hepatic steatosis, lipid droplet, single 39 nucleotide polymorphism 40 41
INTRODUCTION 42
Nonalcoholic steatohepatitis (NASH) cirrhosis is a leading etiology of liver disease 43 worldwide, paralleling the rise in the metabolic syndrome (1). While non-alcoholic fatty 44 liver disease affects approximately 25% of the global population (2), progression to 45 47 nucleotide polymorphism (SNP) in the perilipin 2 (PLIN2) gene, rs35568725, in 48 atherosclerosis and insulin resistance. This SNP codes a Ser251Pro variant and is 49 associated with smaller, more numerous lipid droplets (LD) and reduced lipolysis in 50 macrophages (4). Germline and hepatic loss of PLIN2 have been shown to abrogate 51 hepatic steatosis in animal models of NASH (6) but investigations of the PLIN2 52 Ser251Pro variant have not been reported in the context of liver disease. 53
Our study is the first to investigate rs35568725 in NASH, a disease driven by altered 54 hepatocyte LD metabolism. We determined the prevalence of rs35568725 in a 55 population of adults with and without NASH. To determine if the Pro251 variant of 56 PLIN2 affects LD phenotype, we assessed hepatocyte LDs containing the wild type and 57
Pro251 variants within an in vitro model of hepatic steatogenesis. Our findings suggest 58 rs35568725 conveys risk for NASH in humans and that the mechanism may be due to 59 increased hepatocyte LD burden under steatogenic conditions. 60
61

MATERIALS AND METHODS 62
The Nebraska Biobank, a biorepository with human genomic DNA and linked 63 deidentified health data was utilized. Subjects gave written informed consent and the 64 study was approved by the University of Nebraska Medical Center Institutional Review 65
Board. All subjects age ³ 18 with a diagnosis of NASH excluding other etiologies of liver 66 disease (viral, alcohol, autoimmune, etc.) were included (n=116). Using previous 67 population studies of rs35568725 with minor allele frequencies of 0.06, 0.05 (4), and 68 0.03 (5), and a 5% margin of error with a 95% confidence interval, a sample size of 67 Germantown, MD USA). PCR of the PLIN2 region of interest was performed using 79 forward (5'AGGTTAGAGTCCAGGCCTTAT3') and reverse 80 (5'GAATATGGAGACAGCTCACAGAA3') primers, yielding a 408 bp product verified by 81 agarose gel. Amplicons were purified using ExoSAP-IT™ PCR Cleanup Reagent 82 (ThermoFisher Scientific, Waltham, MA USA) and sequenced using Applied Biosystems 83 3730 DNA Analysis Instrument (Life Technologies, Grand Island, NY USA). Two 84 authors (CSF and LLJ) remained blinded to subject status and used SnapGene (GSL 85 Biotech, Chicago, IL USA) to determine genotypes. 86
In vitro phenotype of PLIN2 variants 87
Using site-directed mutagenesis (QuikChange Lightning, Agilent, Santa Clara, 88 CA USA), the Pro251 allele was inserted into the green fluorescent protein (GFP)-89 PLIN2 plasmid (Addgene #87161). Sequences were verified in forward and reverse 90 directions using primers EGFP-N and SV40pA-R, respectively. Huh7 hepatocytes were 91 reverse transfected with efficiencies > 50% using Lipofectamine2000 (ThermoFisher 92 Scientific, Waltham, MA USA) and steatosis was induced for 48 hours with 0.8mM oleic 93 acid as described (7). Comparative morphometrics of LDs was performed on three 94 independent experiments using confocal (Zeiss LSM 800 with Airyscan, Carl Zeiss, 95
Obercohen, Germany) optical microscopy (Echo Revolve, San Diego, CA USA) and 96
ImageJ software as described (8). LD measurements are expressed as mean +/-one 97 standard deviation. 98
Genetic models and statistical analysis 99
The Hardy-Weinberg equilibrium, allelic odds ratio (OR) and genotypic OR using 100 dominant and recessive models were calculated as reviewed (9). To determine 101 differences between groups for all variables, T-test, Mann-Whitney U and Chi-square 102 test were used as indicated. P values <0.05 were deemed significant. All analyses were 103 performed using GraphPadPrism 8.1.2 (GraphPad Software, La Jolla, CA USA). 104
105
RESULTS 106
Control and NASH groups were matched for gender and age and discordant for 107 comorbidities associated with NASH as expected (supplemental table 1). rs35568725 108 was in Hardy-Weinberg equilibrium (c 2 3.52, p<0.05) in our subject population. Of 116 109 NASH subjects, 81.9% (n=95) lacked, 15.5% (n=18) had a single copy, and 2.6% (n=3) 110 had two copies of rs35568725. Of 67 controls, 92.5% (n=62) lacked, 7.5% (n=5) had 111 one copy and none were homozygous for rs35568725. Due to its lower frequency, 112
rs35568725 was deemed to be the minor allele (a) and wild type was deemed the major 113 allele (A). Allelic OR for NASH conveyed by the minor allele was found to be 2.98 (1.12 6 -7.31, p=0.02) ( Table 2 ). 119
Within transfected Huh7 hepatocytes, overexpressed GFP-PLIN2 and GFP-120 Within a discovery cohort, we found rs35568725 may convey risk for NASH. In our 130 population using a dominant inheritance model, subjects with rs35568725 were 2.74-131 fold more likely to have NASH. This SNP may be an independent risk factor for NASH 132 because within the NASH group, subjects with rs35568725 had similar frequencies of 133 typical NASH comorbidities as subjects without the SNP. rs35568725 may not portend a 134 more aggressive trajectory of liver disease, as carriers had the same rate of cirrhosis as In summary, we demonstrate that a coding SNP of PLIN2, rs35568725, may convey risk 159 for NASH in a discovery cohort. When expressed under steatogenic conditions, human hepatocytes harboring the PLIN2Pro251 variant protein become heavily laden with 161 small, homogenous LDs. More work is ongoing to validate rs35568725 as an 162 independent risk factor for NASH in broader, more diverse populations and to delineate 163 the mechanism(s) of its effects on LD phenotype. 
